出生体重低于500克婴儿早产儿视网膜病变治疗的五年视觉结局:J-CREST多中心队列研究
这项多中心回顾性研究纳入13例(24眼)出生体重低于500克、接受1型早产儿视网膜病变治疗的患儿,随访5年。初始治疗为激光者13眼、抗血管内皮生长因子(VEGF)者11眼。5年时中位最佳矫正视力(BCVA)为0.15 logMAR,73%的眼泪Snellen BCVA≥20/40,27%≥20/20;75%的眼有近视,25%有高度近视。抗VEGF治疗眼近视程度轻于激光治疗眼(P<0.009),BCVA和散光无差异。
要点
- 出生体重低于500克早产儿视网膜病变治疗后5年,27%的眼泪Snellen BCVA≥20/20。
- 5年时75%的眼泪有近视(≤-0.5 D),25%有高度近视(≤-6.0 D)。
- 抗VEGF治疗眼近视程度轻于激光治疗眼(P<0.009),BCVA和散光无差异。
核心结论
- 治疗5年后约四分之一的眼睛Snellen BCVA≥20/20,屈光不正常见。
- 抗VEGF治疗在近视性屈光不正方面可能优于激光治疗。
研究设计与样本
- 多中心回顾性研究,纳入13例(24眼)出生体重低于500克、接受1型早产儿视网膜病变治疗并随访5年的患儿。
- 初始治疗为激光者13眼,抗VEGF者11眼。
主要发现
- 5年时中位BCVA为0.15 logMAR(四分位距0.0-0.5)。
- Snellen BCVA≥20/40者占73%,≥20/20者占27%。
- 中位球镜等效为-2.37(四分位距-6.1至-0.1);75%的眼有近视(≤-0.5 D),25%的眼有高度近视(≤-6.0 D)。
- 中位散光为1.25(四分位距0.9-3.0);46%的眼散光≥1.5 D。
- 抗VEGF治疗眼较激光治疗眼近视程度轻(P<0.009),BCVA和散光无差异(P=0.997,P=0.271)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the 5-year treatment outcomes of retinopathy of prematurity in infants <500 g birth weight and compare laser and anti-vascular endothelial growth factor therapies. METHODS: A multicenter retrospective study comprised 24 eyes of 13 patients treated for Type 1 retinopathy of prematurity, followed for 5 years. Initial treatment was laser and anti-vascular endothelial growth factor in 13 and 11 eyes, respectively. Data collected included sex, birth characteristics, retinopathy of prematurity characteristics at the time of treatment, best-corrected visual acuity (BCVA), spherical equivalent, and astigmatism at 5 years posttreatment. RESULTS: Median BCVA was 0.15 logarithm of the minimum angle of resolution (interquartile range, 0.0-0.5). Snellen BCVA was ≥20/40 in 73% and ≥20/20 in 27% of eyes. Median spherical equivalent was -2.37 (interquartile range, -6.1 to -0.1); 75% had myopia (≤-0.5 D), and 25% had high myopia (≤-6.0 D). Median astigmatism was 1.25 (interquartile range, 0.9-3.0); 46% had ≥1.5 D. Anti-vascular endothelial growth factor-treated eyes showed less myopia ( P < 0.009), with no BCVA or astigmatism difference ( P = 0.997, P = 0.271) compared with laser-treated eyes. CONCLUSION: One-quarter of the eyes exhibited good visual acuity (Snellen BCVA of ≥20/20) 5 years after retinopathy of prematurity treatment. Refractive errors were common. Anti-vascular endothelial growth factor therapy may be superior to laser therapy in myopic refractive error.
引用
- Tomioka M, Murakami T, Okamoto F, et al. FIVE-YEAR VISUAL OUTCOME OF TREATMENT FOR RETINOPATHY OF PREMATURITY IN INFANTS WEIGHING <500 G AT BIRTH: A Multicenter Cohort Study From J-CREST. Retina. 2024. PMID: 38064668. doi:10.1097/IAE.0000000000004016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。